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EXPERIMENTALinfection byintracellular
organisms, either bacteria such as Bacillus
Calmette Guerin (Mathe et al., 1968)
Listeria monocytogenes (Bast et al., 1975)
or protozoa such as Toxoplasma gondii
(Hibbs et al., 1971) or Besnoitia jellisoni
(Lunde and Gelderman, 1971), has been
shown to be associated with a state of
resistance to tumours. The long persistence
ofthe organisms in the body has seemed to
prolong the antitumour effect (Hibbs et al.,
1971). Antibody production (Stjernsward,
1966) and cell-mediated immunity (Miller
et al., 1973), were also stimulated by
those infections. However, positive results
have not always been obtained, and infec-
tions have been shown to depress both the
immune response and resistance to tu-
mour grafts (Piessens et al., 1970). But, in
all instances, the activation of several
macrophage functions was noted (Green-
wood et al., 1971a, b). Dead organisms like
Corynebacterium parvum (Woodruff and
Boak, 1966) and Bordetella pertussis (Lik-
hite, 1974) have also been found to en-
hance macrophage functions and anti-
tumour responses.
Brucella abortus (BA) is an intracellular
parasite mainly of cattle, but, in certain
farming communities, has been shown to
infect man on a very large scale, usually
without clinical disease (Zourbas et al.,
1977). In addition, in Russia an extensive
programme ofhuman vaccination withlive
Brucella has been undertaken using the
strain 19 BA-itself derived from the
Accepte(d 19 Juine 1978
strain B19 of Cotton et al. (1933). The
strain 19 BA was used by Veskova et al.
(1974) in the treatment of a, mouse leukae-
mia. Sublethal doses (2 x 109 organisms
per mouse) injected i.v. on the very day
of leukaemic graft, significantly increased
the survival time ofthe animals. De Santis
and Sega (1976) also treated successfully
tumour-bearing mice by injecting Brucella
abortus.
As we had already shown that large
numbers of dead Brucella could affect
resistance to certain transplanted tumours
in mice, we thought it would be worth-
while to extend these findings to include a
live brucellar vaccine. The aim ofthe work
was to see to what extent a chronic state
of infection might increase resistance to a
tumour graft. Tothisend, smallnumbers of
infectious organisms were inoculated into
mice, after which the appearance of re-
sistance against a graft of lymphoma was
tested. Whatever the mechanisms, the
results showed clearly that the presence of
live Brucella can affect, the outcome of
tumour transplantation.
Brucella abortus strain B19 (lyophilized
vaccine Aborsec, Merieux) was rehydrated,
fractionated into 200 pl aliquots and
stored at -70°C. These tubes of vaccine
were thawed at different times during the
experiments and were shown to contain
roughly the same number of viable organ-
isms. Two different doses of live bacteria,
5 x 102 and 5 x 106, chosen from prelimin-
ary trials, were injected i.v. into mice.ANTI-TUMOUR EFFECT OF LIVE BRUCELLA
C57 B16 xDBA2 Fl hybrid female mice
were used. Groups of 12 mice infected 1 to
6 weeks before, and 3 groups of control
uninfected animals were submitted to
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WEEKS AFTER BRUCELLA INJECTION
FIG.-(a) Number of Brucella(organisms in
spleen (A *) and liver (EO *) 1 to 6 weeks
after infection with 5 x 102 (open symbols)
or 5 x 106 (closed symbols) organisms.
(b) Spleen and liver weight after infection
with 5 x 102 or 5 x 106 organisms.
(c) Survival time of mice injected i.p.
with 103 EL4 lymphoma cells at different
times after infection with 5 x 102 (0) or
5 x 106 (*) organisms. Survival times were
expressed as a percentage of increase over
control. The survival of untreated animals
was 25-6+ 19 days. S indicates that the
differences between control and treated
groups were significant with Student's t test
(P<0 05).
different tests. Four mice of each group
were killed. Their spleens and livers were
removed and weighed and homogenized
with a Potter grinder. The homogenates
were seeded, at different dilutions on
gelose-trypticase-soy medium and after
4 days' incubation, at 37°C the bacterial
colonies were counted. The 8 other mice of
each group received 103 EL4 lymphoma
cells i.p. Their survival was recorded.
As shown in Fig. a, after injecting 5x
102 organisms, the number of bacteria in
the lymphoid organs increased until the
third week. By contrast, in the infection
provoked by 5 x 106 organisms, the maxi-
mal number ofbacteria was found as early
as the first week. Whatever the amount
ofBrucella injected, the infection subsided
within 6 weeks.
The spleen and liver enlarged during the
infection. Their increase in weight roughly
paralleled their content of live Brucella
organisms, but a delay of 1 or 2 weeks
between the 2 curves could be noticed
(Fig. b). The maximal hypertrophy was
reached on the fourth week after infection
with 5 x 102 Brucella and on the second or
third week after 5x 106. The infection was
more florid after the introduction of
5x 106 organisms.
The prolongation ofsurvival time ofthe
lymphoma-bearing mice was significantly
but slightly increased from the third to the
5th week in the mice infected with 5x 102
organisms (Fig. c). The infection by 5x 106
organisms provoked a longer survival,
particularly during the first and second
week after inoculation of the vaccine.
On the whole, it seemed that the re-
sistance to lymphoma was better corre-
lated with the number of infectious
organisms than with the degree of hyper-
plasia ofliver and spleen. This observation
raises the question ofthe role ofthe organ-
isms themselves in the antitumour defence
process. Veskova et al. (1974) suggested
the possibility ofthe secretion by Brucella
ofsubstances inhibiting celldivision. Alter-
natively, immunological defence mechan-
isms directed against Brucella could act
against cancer cells. Brucella infection is,
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however, known to enhance the resistance
against other intracellular organisms non-
specifically (Mackaness, 1964) an effect
probably mediated by macrophages. Mac-
rophages activated by Brucella infection
could also play a non-specific role in the
control of lymphoma growth.
Comparing the present resultswiththose
previously obtained with dead Brucella
(Toujas et al., 1972a, b) it will be noticed
that higher numbers of killed organisms
were required: 22 x 109 (500 pgdryweight)
as against 5 x 102 or 5 x 106live organisms
in the present work. The hyperplasia ofthe
lymphoid organs produced by deadBrucel-
la, mainly associated with proliferation of
marrow-derived cells (Toujas et al., 1972a)
was maximal on the tenth day after bac-
terial injection and correlated with a
diminution of antibody response against
sheep-red-blood-cell antigens. An anti-
leukaemic effect appeared 40 days after
the initial infection (Toujas et al., 1972b).
The use of a live vaccinal strain of B.
abortu8 may be interesting to consider for
possible application in man. The patho-
genicity for man of the strain B19 has
been pointed out by several authors (see
Goret and Pilet, 1962; Roux, 1972). Acute
brucellosis in veterinary surgeons has been
shown to result from accidental contami-
nation during the vaccination of cattle.
The live Brucella vaccine prepared in
U.S.S.R. from strain 19BA has been used
on a large scale in humans. More than 3
millionindividualsreceivedan s.c. inocula-
tion of 3 to 6 x 108 organisms. Few im-
portant side effects were recorded: local
swelling at the site of injection, general
malaise and headache in 8% of cases.
Marked reactions occurred in persons who
had suffered brucellosis in the past (Ver-
shilova, 1961). For Spink et al. (1962) the
inocuousness ofstrain 19 BA was found to
be very disputable. In a trial with 16
volunteers, receiving an s.c. injection of
2-5X108 organisms, 2 disseminated bru-
cellosis cases were found. The application
of the vaccine by scarification (2 x 109
organisms per dose) as described by Zen-
kova (1956), could be tolerated better.
Perhaps quantities smaller than those used
by the authors cited above would be suffi-
cient to induce a non-specific stimulation.
In the present work doses of 5 x 102 were
found to be effective in the mouse. How-
ever, the use of live Brucella as an adju-
vant treatment of cancer in man should be
accepted with caution, and in any case
requires further experimental support.
We are grateful to M. Bonnier for his excellent
technical assistance. Work supported by DGRST.
Contract No. 76-7-1687.
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